|
WO2020154594A2
|
|
Compositions and methods for treatment of human papillomavirus
|
|
WO2018183808A1
|
|
Antiviral therapeutic
|
|
WO2018118586A1
|
|
Antiviral/endogenous combination therapy
|
|
WO2018118585A1
|
|
Antiviral compositions
|
|
WO2018118567A1
|
|
Delivery of antiviral therapies
|
|
WO2018118587A1
|
|
Modified polynucleotides for antiviral therapy
|
|
CA3015353A1
|
|
Viral and oncoviral nuclease treatment
|
|
US2017247703A1
|
|
Antiviral nuclease methods
|
|
US2017247690A1
|
|
Oncoviral treatment with nuclease and chemotherapeutic
|
|
US2017096649A1
|
|
Transgenic nuclease systems and methods
|
|
US2017088828A1
|
|
Compositions and methods for treatment of latent viral infections
|
|
WO2017058796A1
|
|
Antiviral fusion proteins and genes
|
|
US2017087225A1
|
|
Compositions and methods for latent viral transcription regulation
|
|
US2017087224A1
|
|
Delivery methods and compositions
|
|
US2017246260A1
|
|
Modified antiviral nuclease
|
|
CA3000189A1
|
|
Compositions and methods to treat viral infections
|
|
US2016346361A1
|
|
Compositions and methods to treat herpes simplex virus infections
|
|
CA3000170A1
|
|
Antiviral methods and compositions
|
|
US2016346360A1
|
|
Compositions and methods for cell targeted hpv treatment
|
|
US2016346362A1
|
|
Methods and compositions for treating cytomegalovirus infections
|
